je.st
news
Home
› Eli Lilly And Company And Boehringer Ingelheim Announce New Drug Application Filing In The U.S. For New Insulin Glargine Product
Eli Lilly And Company And Boehringer Ingelheim Announce New Drug Application Filing In The U.S. For New Insulin Glargine Product
2013-12-23 00:57:30| drugdiscoveryonline News Articles
Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for LY2963016, an investigational basal (long-acting) insulin
Tags: us
new
company
product
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||